Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHLYS: abatacept for immune checkpoint inhibitor-induced myocarditis
2021-003613-19Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abatacept in immune checkpoint inhibitor myocarditis (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Sustained CD86 receptor occupancy response. Started Jul 2021; status: completed.
02
Drugs
abatacept
03
Conditions
immune checkpoint inhibitor myocarditis
Beyond the preview
Go deeper on 2021-003613-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003613-19.